Keycute (Human Normal Immunoglobulin)

Human Normal Immunoglobulin provides passive immunity by delivering a broad spectrum of pooled IgG antibodies derived from healthy donors. These antibodies bind to and neutralize bacteria, viruses, and toxins, and they also modulate immune system activity, helping to restore normal humoral immunity in individuals with antibody deficiencies.

The dose of Keycute is individualized by the prescribing clinician based on the patient’s weight, IgG trough levels, and clinical response. Typical regimens involve sub‑cutaneous administration of a calculated volume weekly or bi‑weekly, but exact dosing must be determined by a qualified healthcare professional.

The pregnancy category for Keycute is listed as unknown. Use during pregnancy or lactation should only be considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be decided by the treating physician.

To request Keycute, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Keycute is a sub‑cutaneous formulation of pooled human IgG, similar in composition to other immunoglobulin replacement therapies but distinguished by its EU‑sourced plasma and cold‑chain handling. Compared with intravenous IgG, sub‑cutaneous delivery often offers more stable serum IgG levels, fewer systemic reactions, and the convenience of home administration.

Keycute must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to the supplier’s guidelines.

Keycute is supplied as a sterile solution for sub‑cutaneous injection. It is typically injected into the abdomen or thigh using a small‑gauge needle or an infusion set, following aseptic technique. Administration can be performed by a healthcare professional or, after appropriate training, by the patient or caregiver at home.

The most serious adverse events include anaphylactic or severe allergic reactions, thromboembolic complications, renal impairment, aseptic meningitis, and severe thrombocytopenia. Patients should be monitored closely for signs of these conditions, and immediate medical attention is required if they occur.

Keycute is contraindicated in individuals with a known severe hypersensitivity to human immunoglobulin preparations or any of its excipients. It should also be avoided in patients with uncontrolled hyperviscosity, active severe infections, or those who have experienced serious adverse reactions to previous immunoglobulin therapy.